Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Masteam Biotech is a China-based animal health and pharmaceutical chemistry company focused on the research, manufacture, and sale of veterinary active pharmaceutical ingredients and pharmaceutical intermediates. The company operates GMP manufacturing facilities in Wuxue, Hubei, and markets products through a Wuhan-based commercial entity. Its portfolio appears centered on commercial small-molecule veterinary APIs such as florfenicol, tulathromycin, toltrazuril, fipronil, cefovecin sodium, nicarbazine, mequindox, and oxolinic acid. Masteam also presents itself as a CRO/CMO or CDMO-style supplier for APIs and intermediates, with pilot and GMP workshop capabilities and scale from gram quantities to tons. The business is best characterized as a commercial-stage animal health manufacturer rather than a therapeutic biotech developer with a disclosed human clinical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hubei Masteam Biotech.